Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of E-TACE for primary liver cancer
ChiCTR2300076400Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Transcatheter Arterial Chemoembolization in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
Transcatheter Arterial Chemoembolization
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300076400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076400.